UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. reduced its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 21.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,928,086 shares of the company's stock after selling 807,655 shares during the period. Adage Capital Partners GP L.L.C. owned about 12.49% of UroGen Pharma worth $31,184,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of URGN. Price T Rowe Associates Inc. MD raised its position in UroGen Pharma by 2,968.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 393,984 shares of the company's stock valued at $4,197,000 after purchasing an additional 381,145 shares in the last quarter. Silverarc Capital Management LLC grew its position in UroGen Pharma by 24.3% during the 4th quarter. Silverarc Capital Management LLC now owns 1,120,473 shares of the company's stock worth $11,933,000 after purchasing an additional 219,344 shares during the last quarter. Diadema Partners LP purchased a new stake in UroGen Pharma during the 4th quarter worth approximately $532,000. MetLife Investment Management LLC grew its position in UroGen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after purchasing an additional 2,727 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in UroGen Pharma during the 4th quarter valued at approximately $1,454,000. 91.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on URGN shares. The Goldman Sachs Group decreased their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Scotiabank initiated coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective for the company. Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a report on Tuesday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of UroGen Pharma in a research report on Monday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $32.86.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

UroGen Pharma Stock Down 4.0 %

Shares of URGN traded down $0.46 during midday trading on Thursday, reaching $11.18. The stock had a trading volume of 145,429 shares, compared to its average volume of 530,498. UroGen Pharma Ltd. has a 1-year low of $8.94 and a 1-year high of $20.70. The company's fifty day simple moving average is $10.47 and its two-hundred day simple moving average is $11.08. The company has a market cap of $515.33 million, a price-to-earnings ratio of -3.56 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. Equities research analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.